摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氰基-N-[(甲基氨基)羰基]乙酰胺 | 6972-77-6

中文名称
2-氰基-N-[(甲基氨基)羰基]乙酰胺
中文别名
——
英文名称
1-Methyl-3-cyanoacetylharnstoff
英文别名
N-cyanoacetyl-N'-methyl-urea;Cyanessigsaeure-(N'-methyl-ureid);N-Cyanacetyl-N'-methyl-harnstoff;N-Methyl-N'-cyanmethyl-harnstoff;2-cyano-N-[(methylamino)carbonyl]acetamide;2-cyano-N-(methylcarbamoyl)acetamide
2-氰基-N-[(甲基氨基)羰基]乙酰胺化学式
CAS
6972-77-6
化学式
C5H7N3O2
mdl
MFCD00236008
分子量
141.129
InChiKey
JUFPKJMSAUDBBT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    202.5 °C
  • 密度:
    1.213±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.4
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    82
  • 氢给体数:
    2
  • 氢受体数:
    3

SDS

SDS:9773aa2913d3b34915cd8b6b558e838d
查看

制备方法与用途

用途:作为可可碱的中间体。

反应信息

点击查看最新优质反应信息

文献信息

  • Structure-Based Optimization of Potent and Selective Inhibitors of the Tyrosine Kinase Erythropoietin Producing Human Hepatocellular Carcinoma Receptor B4 (EphB4)
    作者:Karine Lafleur、Danzhi Huang、Ting Zhou、Amedeo Caflisch、Cristina Nevado
    DOI:10.1021/jm9009444
    日期:2009.10.22
    hydroxyl groups, to compound 4 has yielded the single-digit nanomolar inhibitor 66, with a remarkable improvement of the ligand efficiency from 0.26 to 0.37 kcal/(mol per non-hydrogen atom). Compound 66 shows very high affinity for a few other tyrosine kinases with threonine as gatekeeper residue (Abl, Lck, and Src). On the other hand, it is selective against kinases with a larger gatekeeper. A 45 ns molecular
    酪氨酸激酶EphB4由于在癌症相关血管生成中的公认作用而成为药物设计的诱人靶标。最近,通过基于高通量片段的对接进入激酶域的ATP结合位点,一系列可商购的黄嘌呤衍生物被鉴定为EphB4的微摩尔抑制剂。在这里,我们利用通过自动对接获得的结合模式来通过化学合成优化这些EphB4抑制剂。仅将两个重原子,甲基和羟基加到化合物4中,产生了一位数的纳摩尔抑制剂66,配体效率从0.26kcal /(mol /非氢原子摩尔)显着提高。化合物66对苏氨酸作为看门者残基(Abl,Lck和Src)的其他酪氨酸激酶具有很高的亲和力。另一方面,它对具有较大网守的激酶具有选择性。EphB4和化合物66的复合物的45 ns分子动力学(MD)模拟提供了通过基于片段的对接获得的结合模式的进一步验证。
  • Ionic liquid mediated one-pot synthesis of 6-aminouracils
    作者:Sunil S. Chavan、Mariam S. Degani
    DOI:10.1039/c1gc15940b
    日期:——
    A novel, one-pot synthesis of 6-aminouracils via in situ generated ureas and cyanoacetylureas in the presence of an ionic liquid catalyst, 1,1,3,3-tetramethylguanidine acetate, is described. The catalyst can be recycled for five consecutive runs without loss of activity. The mechanism for the ring closure of cyanoacetylurea to 6-aminouracil is also discussed.
    本文描述了一种新颖的一锅法合成6-氨基嘧啶-2-酮,方法是通过在离子液体催化剂1,1,3,3-四甲基尿嘧啶醋酸盐存在下原位生成的脲和氰乙酰脲。该催化剂可以连续循环使用五次而不失活。文中还讨论了氰乙酰脲环的闭合机制至6-氨基嘧啶-2-酮的过程。
  • 一种可可碱的制备方法
    申请人:石药集团新诺威制药股份有限公司
    公开号:CN112142738A
    公开(公告)日:2020-12-29
    本发明公开了一种可可碱的制备方法,涉及含嘌呤环系的杂环化合物的制备技术领域。包括如下步骤:‑10~20℃下,在氰乙酸和溶剂中加入草酰氯,反应后浓缩除去溶剂和草酰氯,在0~30℃加入一甲脲和溶剂,加碱作缚酸剂,反应后加水搅拌,过滤得一甲氰乙酰脲;将一甲氰乙酰脲加水溶解,加液碱调pH=8~11,80~100℃反应,生成一甲基4AU;将一甲基4AU溶解在甲酸中,加亚硝酸钠,室温反应后加催化剂,30~70℃保温,反应完毕回收催化剂,母液浓缩回收甲酸,得一甲基FAU;一甲基FAU加水、液碱,闭环反应后加酸调至中性,得3‑甲基黄嘌呤;3‑甲基黄嘌呤经甲化反应、精制,得可可碱。本发明方法反应步骤少、副反应少、收率高、产品质量稳定。
  • Traube,W., Chemische Berichte, 1900, vol. 33, p. 3047
    作者:Traube,W.
    DOI:——
    日期:——
  • Synthesis and lipid-lowering evaluation of 3-methyl-1H-purine-2,6-dione derivatives as potent and orally available anti-obesity agents
    作者:Linhong He、Heying Pei、Liang Ma、Yuzhi Pu、Jinying Chen、Zhuowei Liu、Yan Ran、Lei Lei、Suhong Fu、Minghai Tang、Aihua Peng、Chaofeng Long、Lijuan Chen
    DOI:10.1016/j.ejmech.2014.09.094
    日期:2014.11
    Obesity accompanied with metabolic disorder is often complicated with a strong link of dyslipidemia and insulin resistance, whose indicator is the excess accumulation of triglycerides (TG) in cells. Consideration the idea of lipid-lowering and improving insulin resistance, 34 novel compounds by combination the xanthine scaffold with the chain of Rosiglitazone have been synthesized. Among them, several compounds showed efficiency on reducing TG in 3T3-L1 adipoctyes, and 11c exhibited the most optimal capacity in lipid-lowering and improving obese clinical symptoms in DIO mice. Furthermore, the hydrochloride of 11c (11c center dot HCl) showed excellent bioavailability, 58.94%, over 2 folds than that (28.03%) of 11c, and the anti-obesity effect of 11c center dot HCl at 50 mg/kg dose was better than that of Metjormin at 150 mg/kg dose in DIO mice, almost reversed HFD to a normal level. Thus, 11c center dot HCl might be a potent and orally available anti-obesity agent via alleviating the obese clinical symptoms, body fat, improving serum parameters and insulin resistance and TG clearance in liver. (c) 2014 Published by Elsevier Masson SAS.
查看更多